Gilgamesh Pharma Inc. filed a Form D with the Securities and Exchange Commission on 2026-03-31.
Gilgamesh Pharma Inc. filed a Form D notice of an exempt securities offering with the SEC on March 31, 2026. The filing reports $2.25M sold. Its industry group is Pharmaceuticals. It names Jonathan Sporn (Executive Officer, Director), Andrew Kruegel (Executive Officer, Director), Amy Kruse (Director) (SEC Form D, March 31, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
On the record New York layoffs by employer
Sell to companies like Gilgamesh Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-03-31 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Gilgamesh Pharma Inc.
Free to see. No signup.
More on the people and the money behind Gilgamesh Pharma Inc., from the filings we hold.
Pharmaceuticals raises by companies based in New York, filed within 90 days of this one, largest first.
Get an email when Gilgamesh Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Gilgamesh Pharma Inc. raises, hires or launches. No email unless you switch it on.
Watch Gilgamesh Pharma Inc. →Get the full cited report on Gilgamesh Pharma Inc.
What the filing shows about Gilgamesh Pharma Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Gilgamesh Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Gilgamesh Pharma Inc.'s address as 113 University Place, Suite 1019, New York, NY 10003.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Gilgamesh Pharma Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Gilgamesh Pharma Inc. is a registered filer with the SEC (CIK 2107396) and has filed since 2026-02-04. 4 filings are on record, the latest on 2026-03-31.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Gilgamesh Pharma Inc.'s Form D of 2026-03-31 names Jonathan Sporn, Andrew Kruegel, Amy Kruse and 3 more as its officers, directors or promoters.
Its new offerings report $68.34M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $2.25M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
gilgamesh-pharma-GOLD 2
The title and description the site itself served, answering 200, after redirecting from https://gilgameshpharmaceutical.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Jonathan Sporn is named as Executive Officer and Director on the Form D that Gilgamesh Pharma Inc. filed with the SEC on 31 March 2026, one of 6 people that filing names.
Andrew Kruegel is named as Executive Officer and Director on the Form D that Gilgamesh Pharma Inc. filed with the SEC on 31 March 2026, one of 6 people that filing names.
Amy Kruse is named as Director on the Form D that Gilgamesh Pharma Inc. filed with the SEC on 31 March 2026, one of 6 people that filing names.
Zia Huque is named as Director on the Form D that Gilgamesh Pharma Inc. filed with the SEC on 31 March 2026, one of 6 people that filing names.
Robert Berman is named as Director on the Form D that Gilgamesh Pharma Inc. filed with the SEC on 31 March 2026, one of 6 people that filing names.
Phil Skolnick is named as Director on the Form D that Gilgamesh Pharma Inc. filed with the SEC on 31 March 2026, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2026-03-31 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Gilgamesh Pharma Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Gilgamesh Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gilgamesh Pharma Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Gilgamesh Pharma Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Gilgamesh Pharma Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (gilgameshpharmaceutical.com).
Each opens in a new tab, filled in for Gilgamesh Pharma Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/gilgamesh-pharma-inc-form-d-26000004